Oncology)上，加拿大Odette Sunnybrook癌症中心Hany Soliman博士等人发表了NCT00923897临床II期研究结果。该研究

;房室传导-12隐匿性JEI引起“超常性”房室传导-11隐匿性JEI引起II度窦房传导阻滞-7隐匿性JEI引起II度窦房传导阻滞-8隐匿性JEI引起PR间期交替性改变-6隐匿性

白血病/小淋巴细胞淋巴瘤（CLL/SLL）的2个临床试验的最新结果。最新研究结果以2个口头报告发布：1）来自Ib/II期CLL/SLL患者中ibrutinib单剂量试验（PCYC-1102）的最新安全性及疗效数据；2）来自Ib/II期复发或难治性CLL/SLL患者中ibrutinib与苯达莫司汀

分子流行病学再揭示人类复杂疾病遗传因素及其与环境因素相互作用发挥重要作用,为人类疾病的风险评估、预防和个性化治疗提供依据。全基因组关联分析（GWAS）为全面系统研究复杂疾病的遗传因素掀开了新的一页，为我们了解人类复杂疾病的发病机制提供了更多的线索。科学家已经在肥胖、糖尿病、冠心病、阿尔茨海默、乳腺癌、前列腺癌、肺癌、胃癌等一系列复杂疾病中进行了全基因组关联研究并找到疾病相关的易感基因，我国科学家也在银屑病、精神病和冠心病等方面开展了GWAS研究并取得成效。国家科技部最新公布了“常见重大疾病全基因组关联分析和药物基因组学研究”的863重点项目，吹响了我国大规模开展GWAS研究的号角。为了让更多的相关研究人员，特别是广大研究生了解GWAS的研究原理和方法，学会设计GWAS的研究和分析实验结果，同时在癌症领域分享海内外研究专家们的成功经验，并期待在GWAS方面进行交流合作,复旦大学和美国Van Andel 研究所将于2009年7月12-14日在上海联合举办上海分子流行病学与GWAS国际 研讨会, 期待各位同道免费参加，请有意者及时将回执返回联系邮箱。免注册费（食宿餐饮费用自理）。名额有限，报名从速！时间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆 上海市邯郸路220号，200433
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹 高歌 联系电话： 021-55664495
回执邮箱： GWAS2009@gmail.com
BackgroundRecent success of genome-wide association studies (GWAS) in the U.S. and Europe has lead to the identification of a large number of genetic variants that are associated with disease risk and progression, including those for cancer and cardiovascular diseases. The discovery of these genetic markers not only improves our understanding of disease etiology, but also contributes significantly to risk prediction, early detection, and targeted treatment of diseases.Although GWAS have been used in Chinese populations to identify Chinese-specific risk-associated genetic variants for several common diseases such as breast cancer and psoriasis, many more GWAS are needed for various diseases. A better understanding of the importance of GWAS and a better knowledge of study design and data analysis of GWAS will further promote broad application of GWAS in China. This symposium which will cover genetic epidemiology and GWAS in China is organized to serve this purpose. We have invited a group of experts in this area from the U.S. and China to share their experience in GWAS, and we hope to foster an environment which will encourage an open discussion among all participants.
Objectives• To better understand the potential applications of GWAS
• To address practical issues in study design, implementation, and data analysis of GWAS
• To promote interaction and collaboration among researchers who are interested in GWAS
• To explore other important studies after GWAS: gene-environment interaction, risk prediction, and functional analyses
• To consider issues and implications related to genomic and personalize medicine
Organizing committeeThe organizing committee consists of four members:
Dr. Jianfeng Xu (Co-Chair)
Dr. Daru Lu (Co-Chair)
Dr. Li Jin (Co-Chair ,Advisor)
Dr. Qingyi Wei (Co-Chair, Advisor)
PresentationsSession I: Genetic epidemiology and GWAS of cancer
• Breast cancer in Chinese populations Xiao-ou Shu
• Genetic association studies of skin cancer Jiali Han
• Genetic variants in the MC1R gene and risk of cutaneous melanoma Qingyi Wei
• Genetic association studies of lung cancer in Chinese populations Daru Lu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao Zhou
• Molecular epidemiology of stomach cancer Weimin YeSession II: Genetic epidemiology and GWAS of other diseases
• Genetic association studies of hypertension in Chinese populations Jiang He
• GWAS of Autoimmune Diseases (Psoriasis, etc.) in Chinese populations Wei Huang
• Molecular epidemiology of diabetes in Chinese populations Weiping Jia
• Molecular genetics study of hypertension in Chinese populations Dingliang Zhu
• Molecular epidemiology of hepatitis, liver cirrhosis and hepatocarcinoma Gangqiao ZhouSession III: Post-GWAS studies
• Genetic structure of Chinese population Li Jin
• High-throughput genotyping for GWAS and fine mapping studies Siqun Lilly Zheng
• Molecular genetics study of neural tube defect Hongyan Wang
• Risk prediction using genetic variants in prostate cancer Jianfeng Xu
• Gene-environmental interaction in smoking related cancer Zuo-Feng Zhang
• Cancer Somatic Genomics Bin TehSession IV: Short presentations by participants and discussion
Registration时　　间： 2009年7月12－14日
报到地点： 复旦大学卿云楼宾馆大厅 上海市邯郸路220号 (200433)
会议地点： 复旦大学逸夫楼报告厅
联 系 人： 赵雪莹，高歌 (Shanghai, China)；Tamara Adams (U.S.)
联系电话： 21-55664495 (Shanghai, China)；336-713-7532 (U.S.)
回执邮箱： GWAS2009@gmail.com (Shanghai, China)；tsadams@wfubmc.edu (U.S.)
Invited speakers (alphabetic)• Jiali Han, Ph.D., is an Assistant Professor of Medicine at Harvard Medical School. His major research areas are:
• Genetic epidemiology of skin cancer and breast cancer
• Genome-wide association studies
• Gene-environment interaction• Jiang He, M.D. Ph.D., is a Professor and Chair of Epidemiology, Tulane University School of Public Health., U.S.A. His major research areas are:
• Genetic epidemiology of hypertension
• Gene-nutrition interaction of cardiovascular disease• Wei Huang, Ph.D., is a Professor and Executive Deputy Director of Chinese National Human Genome Center at Shanghai, China. Her major research areas are:
• Genetic susceptibility to autoimmune diseases, cardiovascular diseases and cancer.
• Genome-wide association studies
• Genetic variants and association study• Weiping Jia M.D., is a professor of endocrinology at Shanghai Institute of Diabetes, Shanghai No.6 People’s Hospital, Shanghai Jiaotong University, Her major research area is:
• Molecular endocrinology and diabetes• Li Jin, Ph.D, is a Professor of Genetics and vice President of Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolism diseases
• Genetic markers for population genetics• Daru Lu, Ph.D, is a Professor of Genetics and Vice Dean of School of Life Sciences, Fudan University, China. His major research areas are:
• Genetic and molecular epidemiology of lung cancer and glioma
• Genetics of metabolic disease• Xiao-ou Shu, M.D, Ph,D, is a Professor of Medicine in the Department of Medicine at the Vanderbilt University School of Medicine, U.S.A. Her major research areas are:
• Genetic and lifestyle predictors of cancer and other chronic diseases
• Cohort study methodology
• Incorporating biomarkers in risk prediction• Bin Teh, M.D, is a Distinguished Scientific Investigator at Van Andel Institute, U.S.A. His major research areas are:
• Translational cancer research
• Gene expression profiling
• Cancer genome high-throughput sequencing• Hongyan Wang, Ph.D, is a professor of genetics at School of Life sciences, Fudan University, China. Her major research area is:
• Molecular genetics and epidemiology of birth defects (deformity of neural tube, congenital heart disease, etc.)• Qingyi Wei, M.D, Ph.D, is a Professor of Epidemiology at The University of Texas M. D. Anderson Cancer Center, U.S.A. His major research areas are:
• Molecular epidemiology of DNA repair, apoptosis, and skin cancer and head and neck cancer
• Genetic susceptibility to cancer
• DNA repair and apoptosis phenotype markers• Jianfeng Xu, M.D, Dr.PH, is a Professor of Epidemiology and Cancer Biology and Director of the Center for Cancer Genomics at Wake Forest University School of Medicine, U.S.A. His major research areas are:
• Genetic epidemiology of prostate cancer
• Genome-wide association and fine mapping analysis
• Risk prediction using genetic markers and other clinicopathologic variables• Zuo-Feng Zhang, M.D., Ph.D, is a Professor of Epidemiology at UCLA School of Public Health, U.S.A. His major research areas are:
• Molecular epidemiology of smoking-related cancers
• Confirmation studies of SNPs identified in genome-wide association studies in smoking-related cancers
• Gene-environmental interaction between genetic markers and environmental factors• S. Lilly Zheng, M.D, is a Professor of Medicine and Director of the Genotyping Laboratory at Wake Forest University School of Medicine. U.S.A. Her major research areas are:
• High-throughput genotyping and sequencing
• Genetic epidemiology of prostate cancer• Gangqiao Zhou, Ph.D, is a Professor of Medical Genetics and Genomics in National Academy of Military Medical Science. His major research area is:
• molecular and genetics of complex diseases• Dingliang Zhu, M.D, is a professor of cardiology at Shanghai Institute of Hypertension, Shanghai, China. His major research area is:
• Molecular and genetics of cardiovascular diseases• Weimin Ye, Ph.D, is a Professor of Medical Epidemiology at Karolinska Institutet, Sweden. His major research areas are: Etiology of upper gastrointestinal diseases
• Topic of presentation: Molecular epidemiology of stomach cancer

Squibb/AstraZeneca研发的SGLT2抑制剂，用于治疗II型糖尿病，FDA于2013年批准了Johnson & Johnson的同类药物卡格列净。多项临床试验评价了达格列净单用，或者联合二甲双胍、格列美脲、吡格列酮、西格列汀、胰岛素治疗II型糖尿病的有效性和安全性。在一项单用达格列净的临床试验中

本期微访谈，丁香园特邀美国知名肿瘤专家@廖新生教授做客微访谈，与大家就“美国的肿瘤治疗体制”这一话题进行交流。欢迎大家踊跃提问，提问请戳：http://i.dxy.cn/talk/cacer-treatment美国肿瘤患者五年生存率为81%，而中国为20%-30

according to the severity assessment. For Grade I (mild) acute cholangitis, initial... should be considered.For Grade II (moderate) acute cholangitis, early

活性，进行了II期临床试验。结果表明替莫唑胺对MGMT启动子甲基化的重度复治晚期结直肠癌患者有效，并且患者可耐受。该研究结果发表在2013年12月的《肿瘤学

： 1.治疗过程无痛苦； 2.如果手法正确治疗效果立竿见影；3.治疗效果持续时间较长。本课程将着重介绍M u l l i g a n C o n c e p t（动态关节松动术） 在腰椎、臀、膝、踝以及脚趾等部位的应用， 课程形式包括讲课、讨论和实践操作。授课教师：魏志荣先生(M u l l i g a n Co n

I-Genie™ ATP荧光检测仪

I-Genie™ ATP荧光检测仪

I-Genie™ ATP荧光检测仪

综述，回顾了过去三十年中所有 II 期实验性试验的研究结果，目的是在假设临床表现的差异对治疗方案或生存没有重大影响的前提下，探索出有效的适用于所有原发灶不明的...良好的沟通是必不可少的。大多数 II 期临床试验将原发灶不明的转移癌的定义局限于上皮癌，它们排除了表现为转移性淋巴瘤、黑色素瘤和肉瘤的患者。然而在实践中，我们做

ISNSRC活动I：专题论坛－肾脏病病理研讨班2010年7月8－10日 北京主办：北大医院肾内科&哈佛大学Brigham & Women医院肾内科承办：北大医院肾内科与会国际专家：Helmut G. Rennke2.ISNSRC活动II：高级论坛－慢性肾脏病

一、报考条件、对象(一) 具有中华人民共和国国籍;(二) 年龄一般为 18 周岁以上，35 周岁以下 (1983 年 12 月 31 日至 2000 年 12 月 31 日期间...

欧洲动脉粥样硬化协会（EAS）始建于1964年，旨在“推进和交流有关动脉粥样硬化疾病成因、自然史、治疗和预防的相关知识”。动脉粥样硬化成为越来越重要的问题。组织机构大会组团推广机构：联合国际医院协作中心会议时间：2014年5月31日-6月3日会议地点：西班牙 马德里参会报名联系方式咨询电话：010-56126719联系人：李女土Email:hongshengtiaxia@sina.cn

勃林格殷格翰公司今日宣布其II阶段研究，评估实验性噻托溴铵经每日一次雾化吸入给药的研究结果。受试者为中度持续性哮喘的青少年。数据发表于2012...和成人患者中的潜在作用。结果来自为期4周的II阶段随机双盲安慰剂对照的不完全交叉研究。剂量范围研究评估了105例12-17岁中度持续性哮喘，吸入